Last reviewed · How we verify
Amacetam — Competitive Intelligence Brief
phase 2
pramiracetam
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
Amacetam (PRAMIRACETAM). Pramiracetam works by increasing the activity of certain neurotransmitters in the brain, such as acetylcholine, to enhance memory and cognitive function.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Amacetam TARGET | PRAMIRACETAM | phase 2 | pramiracetam |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (pramiracetam class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Amacetam CI watch — RSS
- Amacetam CI watch — Atom
- Amacetam CI watch — JSON
- Amacetam alone — RSS
- Whole pramiracetam class — RSS
Cite this brief
Drug Landscape (2026). Amacetam — Competitive Intelligence Brief. https://druglandscape.com/ci/pramiracetam. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing